JAK2 and myeloproliferative neoplasm: In 2005, a somatic activating point mutation in Janus kinase 2 (Jak2)—Jak2V617F was discovered in Philadelphia chromosome-negative myeloproliferative neoplasm (MPN) patients [1–4, 5].